Dementia with Lewy Bodies Flashcards
1
Q
LBD
A
- accounts for 15-20% dementia
- presents with progressive dementia and PD symptoms
- fluctuation in level of attention and severity of cognitive impairment seen
2
Q
Lewy bodies
A
- eosinophilic intracytoplasmic neuronal inclusion bodies
- made of abnormally phosphorylated neurofilament proteins
- aggregated with ubiquitin and alpha-synuclein
3
Q
Central feature of LBD
A
-progressive cognitiive decline of sufficient magnitude to interfere with normal social or occupational function
4
Q
Core features of LBD
A
- 2 of the floowing
- fluctuating cognition with profound variations in attention and alertness
- recurrent visual hallucinations
- spontaneous motor features of parkinsonism (seen in 70%)
5
Q
Supportive features of LBD
A
- repeated falls due to autonomic dysfunction
- syncope
- transient disturbances of consciousness
- neuroleptic sensitivity
- systematised delusions
- hallucinations in other modalities
6
Q
Paranoid delusions and auditory hallucinations
A
- 65% have paranoid delusions
- 20% have auditory hallucinations
7
Q
Visual hallucinations
A
- seen in 60-80% cases of LBD
- well formed and detailed
8
Q
Sensitivity to antipsychotics
A
- 60% of cases
- 50% individuals have very severe reactions
9
Q
Mean survival rate
A
- approx 8 years
- but can occur over 1-2 years
- 10% decline rate per year in terms of worsening parkinsonism
10
Q
APOE E4 allele
A
-also seen in LBD
11
Q
Scanning
A
- sparing of medial temporal lobes on CT/MRI scan is noted
- medial temporal lobes are preserved in SPECT
12
Q
Memory deficits
A
- short term memory is relatively spared
- attention and frontal subcortical skills and visuospatial ability may be significantly impaired
13
Q
Pathological features of LBD
A
- Lewy related neuritis
- plaques
- NF tangles
- regional neuronal loss in brainsteam (locus cereleus and SN)
- microvacuolation (spongiform change)
- synapse loss
14
Q
Drugs in LBD
A
- cholinesterase inhibitorys improve cognition, delusions, hallucinations in LBD
- Rivastigmine is thought to be good
- cholinesterase inhibitors are not licensed